

Staphylococcus, *Candida*, *Aspergillus*, *Cryptococcus*, *Plasmodium*, *Trypanosoma*, *Leishmania*, a gastrointestinal nematode, a helminth, *Cryptosporidium*, *Toxoplasma*, *Pneumocystis*, *Schistosoma*, or *Strongyloides stercoralis*.

(000788) 17. The method of claim 16 wherein the compound is 16 β -bromo-

- 5 3 β -hydroxy-5 α -androstane-17-one, 16 α -bromo-3 β -hydroxy-5 α -androstane-17-one, 16 α -bromo-3 β -hydroxy-5 α -androstane-17-one hemihydrate, 16 β -chloro-3 β -hydroxy-5 α -androstane-17-one, 16 α -chloro-3 β -hydroxy-5 α -androstane-17-one, 3 β ,16 α -dihydroxy-5 α -androstane-17-one, 3 β ,16 β -dihydroxy-5 α -androstane-17-one, 3 β ,16 α ,17 β -trihydroxy-5 α -androstane, 3 β ,16 β ,17 β -trihydroxy-5 α -androstane or
10 3 α ,16 α ,17 β -trihydroxy-5 α -androstane.

(000789) 18. The method of claim 17 wherein the pathogen infection is an intracellular bacterium infection.

(000790) 19. The method of claim 18 wherein the intracellular bacterium infection is a *Mycobacterium* infection and the subject is a human.

- Rule
1.126 15 (000791) ²⁰18. The method of claim 17 wherein the pathogen infection is an hepatitis B virus, poxvirus, Dengue virus, papillomavirus, a togavirus, or a flavivirus infection.

(000792) ²¹20. The method of claim 17 wherein the pathogen infection is a fungus infection or a yeast infection.

- 20 (000793) ²²21. The method of claim 20 wherein the fungus infection or yeast infection is a *Candida*, *Aspergillus*, or a *Cryptococcus* infection and the subject is a human.

(000794) ²³22. The method of claim 17, wherein the pathogen infection is a parasite infection.

- 25 (000795) ²⁴23. The method of claim 22, wherein the parasite infection is a *Plasmodium* infection, a *Trypanosoma* infection, a *Leishmania* infection, a *Schistosoma* infection or a *Cryptosporidium* infection.

- (000796) ²⁵24. The method of claim 23 wherein the compound is 16 α -bromo-3 β -hydroxy-5 α -androstane-17-one or 16 α -bromo-3 β -hydroxy-5 α -androstane-17-one
30 hemihydrate and the infection is a *Plasmodium* infection and the subject is a human.

Rule 1.126

26.
(000797) 25. A composition comprising 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one, 16 α -bromo-2-oxa-3 β -hydroxy-5 α -androstan-17-one, 16 α -bromo-3 β -hydroxy-11-oxa-5 α -androstan-17-one or 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one hemihydrate and one or more nonaqueous liquid excipients, wherein the composition comprises less than about 3% v/v water.

27.
(000798) 26. The composition of claim 25 wherein the composition comprises less than about 0.3% v/v water.

28.
(000799) 27. The composition of claim 25 wherein the one or more nonaqueous liquid excipients are two or more of an alcohol, a polyethylene glycol, propylene glycol and benzyl benzoate.

29.
(000800) 28. The composition of claim 25 wherein the composition is a parenteral formulation.